about
Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision MedicineSingle-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL)Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19bImpact of host genes and strand selection on miRNA and miRNA* expression.Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms.The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNA.Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screeningA compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias.Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma.Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma.Does adiponectin act as an antiangiogenic factor in B-cell chronic lymphocytic leukemia?The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma.Dioxin exposure of human CD34+ hemopoietic cells induces gene expression modulation that recapitulates its in vivo clinical and biological effects.miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo.Gene expression profiling reveals novel protective effects of Aminaphtone on ECV304 endothelial cells.Primary Plasma Cell Leukemia: Identity Card 2016.Notch pathway promotes ovarian cancer growth and migration via CXCR4/SDF1α chemokine system.Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma.Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell line.Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia.HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients.Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines.Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles.Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients.Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression.Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature.Molecular and transcriptional characterization of the novel 17p11.2-p12 amplicon in multiple myeloma.Transcription repression activity is associated with the type I isoform of the MMSET gene involved in t(4;14) in multiple myeloma.In vitro anti-leukaemia activity of sphingosine kinase inhibitor.The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma.Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome.Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease.Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia.A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect.
P50
Q26799238-4F944487-A5EA-4865-8CA3-09CB3AA03592Q28289589-73B780F9-0F6A-4DFF-A8A6-525946B97E0CQ33632244-133A04E0-2CA5-4591-A30E-8DB15678CC20Q34016398-E919A34B-1278-4213-812B-044D23DCE6C8Q34099059-B92B3C05-AF05-4DA2-8697-E568F4A8E21DQ35656801-15218D0B-46FB-401B-8DFD-273EFC3E18C5Q35797331-69D058B2-E422-4279-BB5C-B64515486942Q36413387-96F2F9B9-6DC1-4315-8C9B-035B52B50247Q36414422-E8284E96-6B11-4239-BE2E-C06FD9C290D5Q36439245-FF3EEA92-4AF0-4976-8D32-8F3978510951Q36474588-FAF006D8-62B5-4B45-ACAE-7BA074515DAEQ37424750-7DD746C7-71C2-48A5-9679-86996BA4FEC1Q38332196-80F1D389-238F-4BBF-BA5D-C46C244B3EB2Q38337517-CBE46273-2109-43BE-8715-A0E9F9E465A9Q38395979-2962A420-1681-43D9-B93F-DE679492BFADQ38764048-2B02A5CE-7B0F-4274-A61A-C0A4A3204F5EQ38777790-5E70A0ED-D976-4B5E-980F-3E2A33DA62E0Q38781794-D6755EF4-5ACD-4CCF-88AB-16B4D04A3FADQ38847184-0FEC3A7C-8749-49AE-887B-ED90EEF16D88Q38905792-09CC4CA5-DCA3-4E9E-9F43-39B9FA7CF70CQ39044553-515DF654-3D09-4046-80D0-2E3D1602C568Q39239701-158D6219-F6E6-4603-8BFD-CD9C19328F1EQ39349687-69F75C20-68EF-40D9-94EA-FAB066552FA9Q39430844-EE077023-34D2-4028-A80C-731BFB7D0CF3Q39616165-690CEAEE-0B91-4E1B-889B-6112ED994219Q39729652-68240319-91AF-4B87-B40A-116A40CD8082Q39869539-5D100BD7-FD4C-4264-A8A8-49C2B261E8CCQ39923951-3998FCEC-179B-4CFE-8603-37D9B8A96ADCQ39945195-A797D869-CE2B-42FE-8C82-3EE34FA0F2B6Q40002181-847FE3EA-E5EE-4EB4-B915-623D2D590D8EQ40083717-B4ECC51E-A3D8-48FD-8722-D0E770386997Q40366995-D82BC773-9A17-4AD7-925C-380DD1080A01Q42445577-311E43C6-9B8C-48B0-A352-84A0AD6AA684Q42846656-1191150B-41EA-4A57-8BCA-91129AFEEFD7Q44404066-73653BDB-D47F-4CE9-ABD7-C6DA9A4BC44AQ45330340-87293B14-DFFD-46A9-8DFD-8435EA2384B5Q45392132-44A51B84-52E1-4A86-A17A-F9C5830866B5Q46410066-BA04258E-BD17-41CD-80CA-D357EA411F03Q47812640-E4D22C1C-2DA3-45F5-AC37-06AA1FC3ED65Q47934995-A71BC316-76B7-4BC1-80CC-7989DD7E61A6
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Katia Todoerti
@ast
Katia Todoerti
@en
Katia Todoerti
@es
Katia Todoerti
@nl
Katia Todoerti
@sl
type
label
Katia Todoerti
@ast
Katia Todoerti
@en
Katia Todoerti
@es
Katia Todoerti
@nl
Katia Todoerti
@sl
prefLabel
Katia Todoerti
@ast
Katia Todoerti
@en
Katia Todoerti
@es
Katia Todoerti
@nl
Katia Todoerti
@sl
P106
P1153
12445407000
P21
P31
P496
0000-0001-6687-6871